Cell and Gene Therapy Supply Chain Software Market by Process Component

CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: OVERVIEW

As per Roots Analysis, the global cell and gene therapy supply chain software market is estimated to grow from USD 0.27 billion in the current year to USD 1.32 billion by 2035, at a CAGR of 15.2% during the forecast period, till 2035.

The market opportunity for cell and gene therapy supply chain software has been distributed across the following segments:

Process Component

Sample Collection and Processing Component

Manufacturing Component

Logistics Component

Patient Identification and Treatment Follow-up Component

Type of Software

Enterprise Manufacturing System (EMS)

Laboratory Information Management System (LIMS)

Inventory Management System (IMS)

Cell Orchestration Platform (COP)

Quality Management System (QMS)

Logistics Management System (LMS)

Patient Management System (PMS)

Mode of Deployment

On-premises Deployment

Cloud-based Deployment

Type of End-User

Pharmaceutical Companies

Cell Therapy Labs

Hospitals / Medical Centers

Research Institutes / Biobanks

Scale of Operation

Clinical Scale

Commercial Scale

Key Geographical Regions

North America

Europe

Asia-Pacific

Rest of the World

CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: GROWTH AND TRENDS

Advanced therapies are gradually evolving the face of modern healthcare. These new regenerative and immunotherapy modalities have the potential to improve treatment outcomes by providing viable therapy solutions to patients who currently have limited or no treatment options. Given the nature of these treatment modalities, these therapies have a limited lifespan, even when shipped under temperature-controlled conditions. It becomes increasingly important to track the source of the sample from the time of its collection, current location and manufacturing processes. Following this fact, for the commercial success of such therapies, an effective manufacturing platform and a robust supply chain model are imperative. It is worth mentioning that a sustainable supply chain enables further reductions in the cost of goods and, in turn, prices of such therapies.

The supply chain for innovative therapies is complicated from the outset and given the interdependencies amongst multiple stakeholders, it becomes challenging to manage and streamline the overall process. This has reinforced the need for bespoke and integrated software solutions to help innovators manage the critical intricacies of the supply chain. These software systems have huge potential to manage a multitude of events, maintain the chain of identity and custody, and enable stakeholders to optimize the complex supply chains, while also ensuring compliance with global regulatory standards. Driven by the growing demand for cell and gene therapies and the availability of easy to integrate software solutions to manage cell and gene therapy supply chain, this market is expected to grow significantly in the foreseen future.

CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: KEY INSIGHTS

The report delves into the current state of the cell and gene therapy supply chain software market and identifies potential growth opportunities within the industry. Some key findings from the report include:

Presently, close to 175 cell and gene therapy supply chain software solutions are available in the market; of these, 22% are laboratory information management systems.

Over 20% of the cell and gene therapy supply chain software solutions can be deployed both on-premises and over the cloud, offering flexibility as well as contact-less options for the end-users.

The current market landscape of cell and gene therapy supply chain software providers is fragmented, featuring the presence of both new entrants and established players; majority of these players are based in the US.

The growing interest in this domain is evident from the rise in partnership activity; in fact, 40 partnership deals related to cell and gene therapy supply chain software were inked in 2023.

Several investors, having realized the opportunities associated within supply chain management software domain, have invested USD 3 billion across various funding rounds in the past 10 years.

Driven by the increasing pace of innovation and partnership activity, the market for cell and gene therapy supply chain software is poised to witness steady growth in the foreseeable future.

The cell and gene therapy supply chain software market is anticipated to grow at a CAGR of 15.2%, till 2035; North America is expected to capture the majority share (over 45%) of the market by 2035.

CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: KEY SEGMENTS

Manufacturing of Cell and Gene Therapies Occupy the Largest Share of the Overall Market

Based on the process components, the market is segmented into sample collection and processing, manufacturing, logistics, and patient identification and treatment follow-up. At present, the manufacturing component holds the maximum share of the cell and gene therapy supply chain software market. This trend is unlikely to change in the near future.

Currently, Enterprise Manufacturing System (EMS) Occupies the Largest Share of the Cell and Gene Therapy Supply Chain Software Market

Based on the type of software, the market is segmented into enterprise manufacturing system, laboratory information management system, inventory management system, cell orchestration platform, quality management system, logistics management system and patient management system. At present, enterprise manufacturing system holds the maximum share of the cell and gene therapy supply chain software market. It is worth highlighting that the cell and gene therapy supply chain software market for cell orchestration platforms (COPs) is anticipated to grow at a relatively faster CAGR. This can be attributed to the fact that COPs can be easily integrated with the existing supply chain systems in order to provide end-to-end view of the entire supply chain.

Cloud-Based Software is the Fastest Growing Segment of the Cell and Gene Therapy Supply Chain Software Market During the Forecast Period

Based on the mode of deployment, the market is segmented into on-premises deployment and cloud-based deployment. It is worth highlighting that, at present, on-premises deployment holds a larger share in the cell and gene therapy supply chain software market. However, in the coming years, the market for cloud-based deployment is expected to grow at a relatively faster CAGR.

Software Solutions Used to Manage Clinical Operations Occupies the Largest Share of the Cell and Gene Therapy Supply Chain Software Market

Based on the scale of operation, the market is segmented into clinical and commercial scales. At present, software solutions used to manage clinical operations hold the maximum share of the cell and gene therapy supply chain software market. However, in the coming years, the software solutions used to manage commercial operations are anticipated to grow at a relatively faster pace. This can be attributed to the expected increase in the market approval of cell and gene therapies which are currently in the clinical stages of development.

Pharmaceutical Companies are Likely to Dominate the Cell and Gene Therapy Supply Chain Software Market During the Forecast Period

Based on the type of end-user, the market is segmented into pharmaceutical companies, cell therapy labs, hospitals / medical centers and research institutes / biobanks. Majority of the current cell and gene therapy supply chain software market is captured by the pharmaceutical companies. It is worth highlighting that the cell and gene therapy supply chain software market for cell therapy labs is anticipated to grow at a relatively faster pace.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the world. Majority of the share is expected to be captured by software solution providers based in North America. It is worth highlighting that, over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.

Example Players in the Cell and Gene Therapy Supply Chain Software Market

Azenta Life Sciences

Biocair

BioLife Solutions

CareDx

Cryoport

Lonza

NMDP BioTherapies

TraceLink

TrakCel

Veeva Systems

Emerson

LabVantage Solutions

Marken

MasterControl

QuickSTAT

Siemens

Stafa Cellular Therapy

Steiner

STEMSOFT Software

TECHNIDATA

Thermo Fisher Scientific

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

Former Chief Business Officer, Mid-sized Company, UK

Chief Clinical Officer, Mid-sized Company, UK

Former Senior Director, Corporate Strategy and Business Development, Very Large Company, US

International Sales and Transfusion Manager, Small Company, France

Former General Manager, Cell Therapy, Very Large Company, US

CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the cell and gene therapy supply chain software market, focusing on key market segments, including [A] process component, [B] type of software, [C] mode of deployment, [D] scale of operation and [E] key geographical regions.

Market Landscape: A comprehensive evaluation of cell and gene therapy supply chain software solutions, considering various parameters, such as [A] type of software, [B] key features, [C] application area, [D] mode of deployment, [E] scale of operation, [F] regulatory guidelines followed and [G] type of end-user. Additionally, it includes a detailed list of developers providing cell and gene therapy supply chain software solutions, along with analysis based on various parameters, such as [H] year of establishment, [I] company size (in terms of employee count), [J] location of headquarters (North America, Europe, Asia-Pacific, and rest of the world) and [K] most active players based on the number of software solutions offered.

Company Competitiveness Analysis: A comprehensive competitive analysis of cell and gene therapy supply chain software solution providers, examining factors, such as [A] developer strength and [B] product portfolio strength.

Company Profiles: In-depth profiles of key cell and gene therapy supply chain software solution providers, focusing on [A] company overviews, [B] software solutions portfolio, [C] financial information, [D] recent developments and [E] an informed future outlook.

Funding and Investment Analysis: A detailed evaluation of the investments made in this domain, encompassing seed funding, venture capital, debt financing, grants / awards, capital raised from IPOs and subsequent offerings.

Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2019, covering acquisitions, platform utilization agreements, service alliances, platform integration agreements, product development agreements, service agreements and other agreements.

Platform Utilization Agreements in Supply Chain Software Solutions Market: An in-depth analysis of the platform utilization agreements inked in this domain since 2019, providing information on the different types of software utilized by end-users in the cell and gene therapy supply chain.

Stakeholder Need Analysis: A qualitative evaluation of the current and future needs of various stakeholders in the cell and gene therapy supply chain, including patients, healthcare providers, collection centers, manufacturers, logistics service providers and regulators. This section provides a summary of the distinct needs of these stakeholders and presents our opinion (drawn from historical and current trends) on the impact of these needs on the supply chain and how the industry is preparing to cater to these needs.

Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting the market growth.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?

Which are the leading companies in this market?

What kind of partnership models are commonly adopted by industry stakeholders?

What are the factors that are likely to influence the evolution of this market?

What is the current and future market size?

What is the CAGR of this market?

How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.

Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.

The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs

Complimentary Excel Data Packs for all Analytical Modules in the Report

Free Updated report if the report is 6-12 months old or older